Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

nobel pharma schweiz ag - deferasiroxum - compresse rivestite con film - deferasiroxum 360 mg, cellulosum microcristallinum, crospovidonum, povidonum k 30, poloxamerum 188, silica colloidalis anhydrica, magnesii stearas, Überzug: crospovidonum, poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 132, e 172 (flavum), pro compresso obducto. - eisenchelator - synthetika

Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

curatis ag - nitisinonum - compresse - nitisinonum 2 mg, glyceroli dibehenas, lactosum monohydricum 116.4 mg, pro compresso. - hereditäre tyrosinämie typ 1 (ht-1) - synthetika

Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

curatis ag - nitisinonum - compresse - nitisinonum 5 mg, glyceroli dibehenas, lactosum monohydricum 113.4 mg, pro compresso. - hereditäre tyrosinämie typ 1 (ht-1) - synthetika

Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

curatis ag - nitisinonum - compresse - nitisinonum 10 mg, glyceroli dibehenas, lactosum monohydricum 108.4 mg, pro compresso. - hereditäre tyrosinämie typ 1 (ht-1) - synthetika

Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

nobel pharma schweiz ag - nitisinonum - capsule rigide - nitisinonum 5.00 mg, amylum pregelificatum, e 133, e 127, e 171, e 110 0.008 mg, gelatina, pro capsula. - hereditäre tyrosinämie typ 1 (ht-1) - synthetika

Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

nobel pharma schweiz ag - nitisinonum - capsule rigide - nitisinonum 10.00 mg, amylum pregelificatum, e 171, e 132, aqua, gelatina, pro capsula. - hereditäre tyrosinämie typ 1 (ht-1) - synthetika

Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

nobel pharma schweiz ag - nitisinonum - capsule rigide - nitisinonum 20.00 mg, amylum pregelificatum, e 171, gelatina, pro capsula. - hereditäre tyrosinämie typ 1 (ht-1) - synthetika

Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

nobel pharma schweiz ag - nitisinonum - sospensione - nitisinonum 4.00 mg, hypromellosum, glycerolum 500 mg, polysorbatum 80, e 211 1.00 mg, acidum tartaricum, aromatica (erdbeeren) cum propylenglycolum, aqua purificata ad solutionem pro 1 ml corresp. natrium 0.1595 mg. - hereditäre tyrosinämie typ 1 (ht-1) - synthetika

Ευρωπαϊκή Ένωση - Ιταλικά - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologici - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - niraparibum, abirateroni acetas - compresse rivestite con film - niraparibum 50 mg ut niraparibi tosilas monohydricus 79.7 mg, abirateroni acetas 500 mg corresp. abirateronum 446 mg, hypromellosum, natrii laurilsulfas, lactosum 240.54 mg ut lactosum monohydricum, crospovidonum, cellulosum microcristallinum silicificatum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, glyceroli monocaprylocapras, talcum, natrii laurilsulfas, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso obducto corresp. natrium 5.05 mg. - prostatico - synthetika